By using the body’s immune system, Anixa Biosciences, Inc. is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of approximately 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID®(lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.
BioInvent International AB (OMXS: BINV), is focused on the discovery and development of novel and first-in-class and best-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program BI-1206 is currently in Phase l/lla for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells of the tumor microenvironment relevant to solid and hematologic cancers, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials.
About Celyad Celyad is a clinical-stage biopharmaceutical company focused on the development of specializedCAR-T cell-based therapies and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell autologous and allogeneic platforms have the potential to treat a broad range of solid and hematologic tumors. After having demonstrated safety, its lead oncology autologousCAR-TtherapyCYAD-01 (CART NKG2D) is now currently being evaluated in several Phase I clinicaltrials to assess the clinical activity of multiple administrations of autologous CYAD-01 cells in solid cancer (metastatic colorectal cancer) and hematological tumors (acute myeloid leukemia) with or without being concurrently administered with standard-of-care treatments (preconditioning chemotherapy). Concomitantly, Celyad is developing CYAD-101, first-in-class, investigational, non-gene edited, allogeneic (donor derived) CAR-T therapy co-expressing the CAR-T NKG2D and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule). The expression of TIM reduces signaling of the TCR complex and could therefore reduce or eliminate Graft versus Host Disease (GvHD). CYAD-101 is evaluated in a Phase I trial for the treatment of patients with mCRC. Preliminary results are expected in second half of 2019. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all underthe ticker symbol CYAD
We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures.
Convergent R.N.R (CRnR) is an Israeli company engaged in developing a lens based system attached to an ordinary X-ray source (sources which are commercially used for X-ray imaging) to converge X-rays of kV range of photon energy towards a volume of interest for the purpose of radiotherapy and radiosurgery of tumors. The technology is based on a proprietary X-ray lens design, which converges only the 60 keV photon energies, all other energies (either lower or higher than 60 keV) are absorbed by the metal single crystals that construct the lens. CRnR collaborate with MD Anderson Cancer Center (MDACC), the largest and most prestigious world Cancer Medical Center, that performs the medical tests of our technology. The lenses are serving as a platform for variety of medical applications: - Radiotherapy and Radiosurgery (The first implementation of our technology). - Pediatrics Cancer Treatment. - Converging-imaging. - Imaging while Treating. - New approach for Breast Cancer (3 Dimensions Monochromatic Imaging & Treatment by immediate "sniping" at the tumor). - Denervation (Heart Fibrillation, Renal Denervation). - Brain-disorders in a single shot (Parkinson, etc..). - Wet-AMD (Age-related Macular Degeneration) and Eye Melanoma. - GNP (Gold Nano-Particles) radio sensitization. - Mobile/Transportable Systems (including Off-Road systems).
Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers, autoimmune disorders and infectious diseases. We design biologics to engage and modulate the activity of antigen-specific T cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects.
We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs.
Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
EXUMA Biotechnology is a clinical stage immuno-oncology company pioneering the development and commercialization of logic gate-controlled T cell therapies for the treatment of cancer in the Greater China markets. The Company’s platform technologies have generated a continuous pipeline of novel product candidates that feed into proprietary manufacturing systems to generate genetically engineered T cells capable of identifying and killing tumor cells. Product candidates are being developed on two delivery solutions, CCT3 and CCT4, which are intended to serve distinct market segments. The Company believes its logic gate-controlled CAR-T cell technology may achieve greater specificity against solid tumors while minimizing damage to normal tissues in the body. To date, CCT301-38-AXL and CCT301-59-ROR2 CAR-T cell therapies have been tested in metastatic renal cell carcinoma through investigator-initiated trials (IITs) in a precision medicine directed umbrella trial. The Company plans to expand these clinical product candidates into multicenter trials under a centralized regulatory pathway in 2019, with a third undisclosed target intended for first in human filing by year end. The Company’s next generation CCT4 CAR-T delivery systems are currently in development to provide broader patient access through reduced cost and complexity of patient care. EXUMA Biotechnology was formed in 2016 as a Cayman Special Economic Zone Company, with capitalization and exclusive technology licenses from F1 Oncology, Inc with recent asset acquisitions from the PRC. The Company’s wholly owned subsidiaries, EXUMA Biotechnology Hong Kong Ltd. and Shanghai EXUMA Biotechnology Ltd., are responsible for development, manufacturing, quality, clinical, regulatory, and commercial operation with facilities located in Shanghai and Shenzhen, PRC.
Small but tough. Faron is a clinical stage biotech tackling some of the worst diseases on the planet such as ARDS, pancreatic and colorectal cancer, glioblastoma and tuberculosis. We are backed up with world leading science in vascular integrity, leucocyte migration and tumor biology, accompanied with exceptional dedication to the cause.
As we say at Genocea, “targets matter.” We are currently advancing a growing pipeline of innovative cancer therapies that demonstrate that target – or antigen – selection plays an important role in driving immunotherapy efficacy. Our unique ATLAS™ technology platform allows us to identify and characterize immunotherapy targets based on each individual’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude “inhibitory” neoantigens that appear to exert an immunosuppressive effect on the patient. Our two lead programs are built from our ATLAS insights: • GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and • GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. We are currently exploring a variety of partnership opportunities both to accelerate development of GEN-009, GEN-010, GEN-011 and our shared antigen vaccine programs, as well as to expand the applications for our ATLAS technology, including antigen / TCR discovery and ATLAS-enhanced biomarker / drug development.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Immunicom, Inc. is a privately-held medical technology company located in San Diego, CA focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases.
Immunicom has received FDA Breakthrough Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer. The solution in development is a blood-filtering technology for Immunicom’s proprietary immunotherapy solution, Immunopheresis™. The Immunopheresis™ treatment removes proteins that suppress the immune system and protect tumors. The treatment has the potential to effectively treat a wide variety of cancer types including those that have not responded to other treatment strategies including other drug and biological-based immunotherapy options, and to do so with fewer side effects.
Immunicom seeks to leverage its technology to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world.
In May 2019, Immunicom will begin a 170-patient, multi-center, triple-negative breast cancer study in Europe. This pivotal study will include three arms: mono-therapy, combination chemotherapy, and a chemotherapy-only control. In September, 2019, the Company will begin an additional single-center trial in Israel focused on dosing and combination therapy with a checkpoint inhibitor. The Israeli study will cover multiple solid tumor cancer types.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics. Kleo’s compounds directly engage patients’ immune system to target and destroy cancer cells. Unlike biologics, Kleo’s compounds are smaller and more versatile, leading to potentially improved safety and efficacy. They are faster and less costly to design and produce, particularly against novel targets. The company is advancing several drug candidates based on its proprietary technology platforms, each of which is modular in design enabling rapid generation of novel immunotherapies that can be optimized against cancer and other diseases or enhance the properties of existing biologics.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.
NOXXON is a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment. The company's oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in December 2018 and further studies are being planned in these indications. NOXXON has initiated preparations for an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset, NOX-E36 is a Phase 2 ready TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination.
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases.
Using our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We have strong partnerships with Novartis, Sanofi Group, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations and Orchard Therapeutics, providing them with access to our intellectual property, state-of-the-art production facilities and expertise, and, in addition, we have licensed products and technology rights to Boehringer Ingelheim, Sanofi and Axovant. These partnerships provide us with multiple income streams, consisting of upfront milestone payments, development and production fees and potential royalties on future product sales. We plan to progress our wholly-owned products via spin-outs and out-licensing opportunities, while continuing to invest in our LentiVector® platform. We plan to continue our preclinical R&D to discover new potential products.
Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on our self-delivering RNAi (“sd-rxRNA®”) therapeutic platform. The Company’s efforts are focused on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intra-tumoral injections. We aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer, and to make tumors more susceptible to such attacks, and ultimately provide patients battling cancers with a powerful new treatment option that goes beyond current treatment modalities.
Refuge Biotech utilizes gene editing technologies, CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), to develop intelligent therapeutic cells that can make decisions inside the body. Contrary to CRISPR’s way of editing the DNA by cutting, Refuge is leveraging their proprietary receptor-dCas platform to create genetically programmable switches that have the ability to regulate multiple gene expressions. By turning the CRISPRi/a systems into an immuno-oncology tool, Refuge can treat a broad range of cancers, including lymphomas and solid tumor cancers, safer and more precisely than other immunotherapies. Refuge aims to change the current paradigm by combining different cancer treatment modalities into a single cell without damaging the DNA.
SciNote LLC develops reliable software solutions that connect and empower scientists. Its flagship product, SciNote, is a digital lab notebook that is currently among the top 5 software solutions of its type in the world. SciNote enables scientists toreplace their paper notebook with a digital lab version and offers new possibilities for scientific data management and manuscript writing. It is also able to connect with lab instruments and other software solutions used in the labs, to provide users with a unique platform that enables data to be stored safely and shared among collaborators. Founded in 2016, the Company is a joint venture between Gilson Inc, one of the leading companies for automation instrumentation and chromatography systems, and BioSistemika LLC, one of the top software development companies for life science laboratories. SciNote LLC is led by CEO, Klemen Zupancic, PhD and headquartered in Middleton, WI with offices in Ljubljana, Slovenia.
Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs.
The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. The clinical development pipeline is focused on oncology and fibrosis indications.
Through the internal research and collaborations with prominent labs at NIH, Johns Hopkins, Duke, University of Maryland and Penn State, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and unique PNP delivery system.
The management team collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery.
SIWA is a pre-clinical stage company. Our focus is on aggressive cancers, and we are completing requisite work to file an IND for an identified cancer within the next year. We have in vivo results showing that treatment with SIWA 318M, a mouse homolog of therapeutic candidate, SIWA 318H, statistically significantly: (1) inhibited cancer metastasis without increasing primary tumor growth in a 4T1 triple negative breast cancer model; and (2) consistent with the evidence that removal of SCs is a normal part of the regeneration process, it (a) restored muscle mass in normally aged mice back to a level comparable to young mouse controls; and (b) reduced SCs by two-thirds from the level of very old mice down to the level of young mouse controls. SCs are causally implicated in age-related dysfunction and in degenerative diseases including cancer. SCs act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them should improve healthspan and lifespan. Our SIWA-identified advanced glycation end product (“AGE”) target antigen is common to both senescent cells (“SCs”) and cancer cells as both cell types have in common (a) an abnormally high level of glycolysis and (b) presence of our marker which is produced by glycolysis. Our mAb can thereby target both SCs and cancer cells for immune destruction. Because SCs in the tumor microenvironment feed, promote progression and suppress immune removal of cancer cells, SIWA 318H has a unique capability of killing cancer cells and eliminating the microenvironment which favors tumor initiation, progression and metastasis.
Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Our innovative and proprietary technology, called the T Cell-Antigen Coupler (or TAC), possesses advantages over other approaches because of the differentiated structure and biology of the TAC construct. In contrast to the Chimeric Antigen Receptor (CAR), the TAC receptor signals through the T cell receptor complex and thus leverages the endogenous activating and counter-regulatory pathways used by T cells normally during engagement with target cells. Thus the TAC provides a nuanced and regulated activation of the T cell. We believe this activity will translate to improved clinical safety and efficacy in both solid tumors and hematological malignancies, as we have seen evidence of this in preclinical models. Our lead program is entering the clinic in 1H19. Additionally, we are pursuing development of an allogeneic platform.
VCN Biosciences is a clinical-stage company focused on the immuno-oncology space harnessing the power of oncolytic viruses. Our next generation oncolytic adenoviruses are designed to obtain clinical activity by systemic administration and remodel complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and immune system. Our scientists have developed a flexible technological platform with a solid IP position (4 exclusive patent families) and our candidates are currently tested in different clinical trials showing their mechanism of action and activity.